4.5 Article

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen

Journal

MOLECULAR CANCER RESEARCH
Volume 19, Issue 10, Pages 1613-1621

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-21-0146

Keywords

-

Funding

  1. European Research Council [ERC 787925]
  2. Oncode Institute
  3. Center for Cancer Genomics

Ask authors/readers for more resources

Pro-senescence therapies are being considered for cancer treatment, with the challenge of identifying additional targets to induce senescence in cancer cells. A suicide switch system is presented for genome-wide CRISPR screening in growth-arrested subpopulations by eliminating proliferating cells. Autophagy-related proteins are identified as targets for senescence induction and combining ULK1 inhibition with the senolytic drug ABT-263 leads to apoptosis in cancer cell lines.
Pro-senescence therapies are increasingly being considered for the treatment of cancer. Identifying additional targets to induce senescence in cancer cells could further enable such therapies. However, screening for targets whose suppression induces senescence on a genome-wide scale is challenging, as senescent cells become growth arrested, and senescence-associated features can take 1 to 2 weeks to develop. For a screen with a whole-genome CRISPR library, this would result in billions of undesirable proliferating cells by the time the senescent features emerge in the growth arrested cells. Here, we present a suicide switch system that allows genome-wide CRISPR screening in growth-arrested subpopulations by eliminating the proliferating cells during the screen through activation of a suicide switch in proliferating cells. Using this system, we identify in a genome-scale CRISPR screen several autophagyrelated proteins as targets for senescence induction. We show that inhibiting macroautophagy with a small molecule ULK1 inhibitor can induce senescence in cancer cell lines of different origin. Finally, we show that combining ULK1 inhibition with the senolytic drug ABT-263 leads to apoptosis in a panel of cancer cell lines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available